Latest monoclonal antibodies News

Future Cancer Treatment And Fertility
Babies in WA will soon be immunised against RSV – but not with a vaccine
Springfield Steps Up To Fight Breast Cancer
Promising Development for Breast Cancer Patients
Australian scientist recognised as emerging talent
WHO endorses landmark public health decisions on Essential Medicines for Multiple Sclerosis
Alzheimer’s drug donanemab has been hailed as a ‘turning point’ for treatment. But what does it mean for people with the disease?
Nirsevimab unanimously recommended by FDA Advisory Committee for the prevention of RSV lower respiratory tract disease in infants
WHO and Republic of Korea sign landmark agreement to boost biomanufacturing capacity
Wonder drug-capsule may one day replace insulin injection for diabetics
Update to contractual arrangements between AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi
Antibody targets omicron and other SARS-CoV-2 variants
Update on effectiveness of monoclonal antibodies against COVID variants
New tool in arsenal against Covid is being put to t
Monash University and Ono Pharmaceutical Announce Collaboration Agreement
What are skeletal related events?
Beyfortus approved in EU for prevention of RSV lower respiratory tract disease in infants
New Omicron subvariant largely evades neutralizing antibodies
Evusheld long-acting antibody combination approved in EU for treatment of Covid
Evusheld long-acting antibody combination recommended for approval in EU for treatment of Covid
Beyfortus recommended for approval in EU by CHMP for prevention of RSV lower respiratory tract disease in infants
Evusheld long-acting antibody combination approved for prevention and treatment of Covid in Japan
RSV prevention finally in reach after 20 years of research at Telethon Kids Institute
WHO makes new recommendations for Ebola treatments, calls for improved access
Lack of innovation set to undermine antibiotic performance and health gains
AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against Covid
TGA receives application for an increased dose of GlaxoSmithKline’s Covid treatment sotrovimab for BA.2 Omicron sublineage
Promising nose spray could prevent and treat Covid
AstraZeneca’s antibody combination, Evusheld▼ authorised for use
New hope for babies born with heart defect
Sotrovimab shown to cause Covid treatment-resistant mutations
AstraZeneca’s Evusheld Granted Provisional Approval For Pre-Exposure Prophylaxis Of Covid
TGA provisionally approves AstraZeneca’s combination therapy – for pre-exposure prevention of Covid
Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants
Study Reveals How Migraine Pain Signals Are Generated-and Blocked
Researchers Identify Osteoarthritis ‘Pain Pathway’
WHO recommends two new drugs to treat Covid
TGA grants provisional determination to AstraZeneca Pty Ltd for Covid prophylaxis and treatment, tixagevimab and cilgavimab
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant 23 December
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant
Evusheld long-acting antibody combination authorised for emergency use
New analyses of two AZD7442 Covid Phase III trials in high-risk populations confirm robust efficacy and long-term prevention
TGA grants provisional determination to AstraZeneca Pty Ltd for Covid preventative treatment, tixagevimab and cilgavimab
CSL Research and Development Day 2021
Research-industry partnership to advance biologic therapies
Australia secures additional Covid treatments
AZD7442 request for Emergency Use Authorization for Covid prophylaxis filed in US
Researchers Illuminate Working Mechanism of Important Drug Target Proteins